WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 5 fonti

Takeda found liable over antitrust plot to delay generic constipation drug

Japanese drugmaker was accused by US pharmacies, retailers of 'pay-for-delay' scheme

Raccontata daasia.nikkei.comfiercepharma.comvalor.globo.combenzinga.compharmaceutical-technology.com

Confronto fonti

5 prospettive sulla stessa storia
AI · summaries
asia.nikkei.comStai leggendo1 mesi fa

Takeda found liable over antitrust plot to delay generic constipation drug

Japanese drugmaker was accused by US pharmacies, retailers of 'pay-for-delay' scheme

originale

Timeline cronologica

  1. lunedì 18 maggio 2026·asia.nikkei.com

    Takeda found liable over antitrust plot to delay generic constipation drug

    Japanese drugmaker was accused by US pharmacies, retailers of 'pay-for-delay' scheme

  2. martedì 19 maggio 2026·fiercepharma.com

    Takeda slapped with $885M verdict in pay-for-delay antitrust case

    Takeda plans to appeal after a federal jury found it liable in a landmark pay-for-delay antitrust case and ordered the Japanese drugmaker to pay $885 million in damages, a figure…

benzinga.com
1 mesi fa

Jury Hits Takeda With $885 Million Antitrust Verdict - Takeda Pharmaceutical Co (NYSE:TAK)

Takeda faces nearly $885 million jury verdict in AMITIZA antitrust case and plans post-trial motions and appeal.

Leggi questa versione → originale
pharmaceutical-technology.com1 mesi fa

Takeda faces $885m hit after landmark pay-for-delay lawsuit verdict - Pharmaceutical Technology

Takeda confirmed it would appeal the outcome, stating that the case “lacks merit”.

Leggi questa versione → originale
fiercepharma.com1 mesi fa

Takeda slapped with $885M verdict in pay-for-delay antitrust case

Takeda plans to appeal after a federal jury found it liable in a landmark pay-for-delay antitrust case and ordered the Japanese drugmaker to pay $885 million in damages, a figure that could be roug | Takeda plans to…

Leggi questa versione → originale
valor.globo.com1 mesi fa

Farmacêutica Takeda enfrenta indenização bilionária por atrasar genérico nos EUA

Farmacêutica Takeda enfrenta indenização bilionária por atrasar genérico nos EUA

Leggi questa versione → originale
  • martedì 19 maggio 2026·valor.globo.com

    Farmacêutica Takeda enfrenta indenização bilionária por atrasar genérico nos EUA

    Farmacêutica Takeda enfrenta indenização bilionária por atrasar genérico nos EUA

  • martedì 19 maggio 2026·benzinga.com

    Jury Hits Takeda With $885 Million Antitrust Verdict - Takeda Pharmaceutical Co (NYSE:TAK)

    Takeda faces nearly $885 million jury verdict in AMITIZA antitrust case and plans post-trial motions and appeal.

  • mercoledì 20 maggio 2026·pharmaceutical-technology.com

    Takeda faces $885m hit after landmark pay-for-delay lawsuit verdict - Pharmaceutical Technology

    Takeda confirmed it would appeal the outcome, stating that the case “lacks merit”.